<DOC>
	<DOCNO>NCT02019095</DOCNO>
	<brief_summary>In recent experimental study , investigator show growth factor Activin A express lung rat acute respiratory distress syndrome ( ARDS ) level comparable determine bronchoalveolar ( BAL ) lavage fluid patient ARDS . In study , administration Activin A inhibitor Folistatin result attenuation histological damage ARDS-afflicted rat lung . The precise role Activin A/Folistatin acute respiratory failure associate acute lung inflammatory pathology elucidate yet . Therefore , purpose present , observational study investigate role Activin A/Folistatin respiratory failure due ARDS and/or ventilator-associated pneumonia ( VAP ) , also relation biochemical marker , cytokine surfactant-related protein .</brief_summary>
	<brief_title>Clinical Biological Markers Acute Respiratory Failure</brief_title>
	<detailed_description>Rationale Survival Acute Respiratory Distress ( ARDS ) associate clinical ( e.g . age , sepsis , organ failure ) biological factor . The latter include inflammatory mediator ( e.g . cytokine ) , factor activation/damage capillary endothelium ( e.g . von Willebrand factor ) alveolar epithelium ( e.g . intracellular adhesion molecule-1 ) , factor associate coagulation/fibrinolysis cascade ( e.g . protein C ) . These biochemical marker previously associate duration mechanical ventilation , ARDS-induced organ dysfunction/failure , survival patient . A combination biochemical clinical marker might useful prognostic tool ARDS . In recent experimental study , investigator show growth factor Activin A express lung rat ARDS level comparable determine bronchoalveolar ( BAL ) lavage fluid patient ARDS . In study , administration Activin A inhibitor Folistatin result attenuation histological damage ARDS-afflicted rat lung . The precise role Activin A/Folistatin acute respiratory failure associate acute lung inflammatory pathology elucidate yet . Therefore , purpose present , observational study investigate role Activin A/Folistatin respiratory failure due ARDS and/or ventilator-associated pneumonia ( VAP ) , relation biochemical marker . Methods Patients The study protocol approve Institutional Review Board Evaggelismos General Hospital , Athens , Greece . A study information sheet detail associate potential risk benefit provide first degree relative eligible patient . Subsequently , follow detailed discussion study investigator ( ) , write informed consent request . Continuous monitoring patient include electrocardiographic lead II , intraarterial pressure [ and/or cardiac index ( PICCO plus , Pulsion Medical Systems , Munich , Germany ) - concordance clinical indication ] peripheral oxygen saturation ( SpO2 ) . Maintenance anesthesia achieve intravenous midazolam propofol and/or fentanyl remifentanyl . Neuromuscular blockade ( cisatracurium ) use concordance recent recommendation , and/or part treatment prescribe attending physician . The follow-up patient last 60 day hospital discharge ( occurs earlier day 60 study enrollment ) . Conventional Mechanical Ventilation ( CMV ) Strategy Patients eligible study initially CMV ( [ Siemens 300C ventilator ( Siemens , Berlin , Germany ) , follow FiO2/PEEP combination : 0.5/10-12 cm H2O , 0.6/14-16 cm H2O , 0.7/14-16 cm H2O , 0.8/14-16 cm H2O , 0.9/16-18 cm H2O , 1.0/20-24 cm H2O . In patient body mass index &gt; 27 kg/m2 intra-abdominal pressure &gt; 15 cmH2O , positivity end-expiratory transpulmonary pressure confirm use esophageal balloon catheter ( whenever feasible ) . Regarding patient PaO2/FiO2 le 200 mmHg , use high PEEP consistent recently publish data relevant survival benefit . The tidal volume 5.5-7.5ml/kg predict body weight maximum allowable plateau pressure ≤32 cmH2O . The goal tidal volume plateau pressure 6.0 ml/Kg predict body weight 30 cmH2O , respectively , provide below-mentioned gas exchange goal achievable . Respiratory rate adjust arterial pH ( pHa ) range 7.20 7.45 inspiratory expiratory time ( I/E ) ratio 1:2 . Oxygenation target follow : SaO2=90-95 % PaO2=60-80 mmHg . The target pHa &gt; 7.20 . In case pHa &lt; 7.20 , breathe circuit deadspace reduce substitute routinely use catheter mount ( Mallinckrodt Dar , Mirandola , Italy ) short angular connector . Additional measure pHa control may include increase tidal volume 8.0 mL/Κg predict body weight respiratory rate 35/min , start continuous bicarbonate infusion implement extracorporeal removal CO2 . PEEP/FiO2 Algorithm 1 . Recruitment Maneuver ( RM ) - Continuous positive airway pressure 45 cmH2O 40 FiO2 1.0 plus subsequent PEEP , FiO2 titration SaO2=90-95 % , PaO2=60-80 ( An additional RM may administer 5 10 hour original RM ) 2 . FiO2 reduction always precede PEEP reduction . 3 . Weaning CMV initiate target gas-exchange achievable FiO2 0.5 PEEP less 8 cmH2O.. 4 . RMs may administer first 5 day study enrollment . Rescue oxygenation Rescue oxygenation methodology may include high frequency oscillation ( HFO ) with/without tracheal gas insufflation ( TGI ) , prone positioning , inhale nitric oxide , extracorporeal membrane oxygenation . The duration rescue oxygenation session least 10 hour allowance unlimited extension PaO2 &lt; 60 mmHg . Rescue initiation criterion : PaO2 &lt; 60 mmHg 30 min FiO2=1.0 , absence reversible cardio-respiratory pathology and/or ventilator malfunction . Bronchoscopies Bronchoalveolar lavage ( BAL ) BAL ≤100 mL perform day 1 5 post-enrollment . Patients eligible BAL PaO2/FiO2 exceed 100 mmHg 12 hour intubate orotracheal tube internal diameter ≥8.5 mm , tracheostomy tube . An ( additional ) RM perform fiberoptic bronchoscopic procedure . BAL fluid sample use microbiological culture , cell count , determination biological marker . On day bronchoscopic procedure , remainder blood sample use routine laboratory test , use determination concentration biological marker peripheral blood . BAL fluid study The initial , 20-mL portion BAL fluid aspirate ( correspond bronchial sample ) send microbiological culture , rest store ice-cold tube . Subsequently , BAL fluid filter sterile gauze centrifuge 500 g 15 min 4 degree Celcius . The supernatant use determination concentration Activin A , inflammatory marker , surfactant-related protein . The sediment use total cell count , determination cell type , estimation cell viability Neubauer plate . Both supernatant sediment store -70 degree Celcius . BAL cell study These study conduct centrifuged , hematoxylin-eosine stain preparation cell count least 300 cell type determination . POTENTIAL , PROTOCOL-RELATED RISKS AND THEIR PREVENTION Potential risk : Hypoxemia , Hypercapnia , Hemorrhage , Arrhythmias , Barotrauma . Preventive measure : Pre-oxygenation titration sedation . ContinUous monitor cardio-respiratory parameter bronchoscopy . Bronchoscopy experience endoscopist , presence experience operator conventional ventilator . Use maximal internal diameter tracheal tube , conjunction minimal outer diameter bronchoscope . Potential benefit : BAL culture reliable identification pathogen , consequent use target antibiotic treatment avoidance unnecessarily broad antibiotic regimen . The second BAL sample enable confirmation effectiveness antibiotic treatment documentation reduction concentration colony form unit pathogen . Since investigational intervention present study protocol close departmenal , common clinical practice , investigator apply characterization present study protocol `` observational '' . Patient follow-up Days 1-10 post-enrollment : Recording detailed data respiratory mechanic , gas-exchange , hemodynamics , result laboratory testing , medical treatment . Days 1-60 post-enrollment : Recording organ failure clinical course complication . The final clinical outcome , i.e . survival hospital discharge , also document . Statistical Analysis The normality distribution value biological marker test Kolmogorov Smirnov test . Logistic regression model include biological marker explanatory variable use identify potential effect clinical outcome . In addition , receiver operate characteristic curve construct , order ass prognostic value biological marker respect clinical outcome . Based prior data , investigator estimate complete data minimum 50 patient need study completion . The current protocol constitutes part protocol concurrently terminate NCT01478802</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Pulmonary Surfactant-Associated Proteins</mesh_term>
	<criteria>1 . Ventilatorassociated pneumonia and/or ARDS . 2 . PaO2 fractional inspire oxygen ( FiO2 ) less 400 mmHg . 3 . Age 1875 year . 4 . Body weight least 40 Κg . 1 . Significant air leak . 2 . Severe hemodynamic instability . 3 . Heart disease . 4 . Chronic obstructive pulmonary disease asthma . 5 . Intracranial hypertension . 6 . Chronic interstitial lung disease . 7 . Lung biopsy lobectomy/pneumonectomy current admission . 8 . Prior lung bone marrow transplantation . 9 . Pregnancy . 10 . Immunosuppression . 11 . Bleeding diathesis and/or coagulation disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Pneumonia , Ventilator-Associated</keyword>
	<keyword>Respiratory Distress Syndrome , Adult</keyword>
	<keyword>Pulmonary Surfactant-Associated Proteins</keyword>
	<keyword>activin A</keyword>
</DOC>